This article is more than 5 years old. Information may no longer be current.
Top stories in gastroenterology: New antibiotic effectively treats Crohn’s, fecal microbiota transplantation decreases mortality
Click Here to Manage Email Alerts
Phase 3 trial results indicated the oral antibiotic known as RHB-104 led to durable clinical remission in patients with Crohn’s disease, and a recent study showed that fecal microbiota transplantation lowered mortality in patients with severe and fulminant Clostridioides difficile infection
Read about these findings and more top stories in gastroenterology last week.
Antibiotic confers durable clinical remission in Crohn’s
RHB-104, an oral antibiotic, appeared safe and effective for the treatment of Crohn’s disease, according to the manufacturer. Read more.
Fecal microbiota transplantation decreases mortality in severe, fulminant C. diff
Compared with standard of care, fecal microbiota transplantation decreases mortality among patients with severe and fulminant Clostridioides difficile infection, according to study results. Read more.
Prolonged-release antibiotic prevents abdominal surgical site infections
A novel therapy designed to provide prolonged and constant release of antibiotic helped prevent surgical site infections in patients who underwent abdominal surgeries, according to the manufacturer, PolyPid. Read more.
Non-modifiable risk factors contribute to early-onset colorectal cancer
Several non-modifiable risk factors, such as race, sex and family history all contribute to the development of early-onset colorectal cancer, according to study results. Read more.
Study to evaluate Cologuard’s real-world impact
Exact Sciences and the Mayo Clinic are partnering to conduct a study on the real-world, clinical impact of Cologuard on colorectal cancer screening, according to a press release. Read more.